AUTHORS
Yu Wang, Xiaosu Zhao2, Ying-Jun Chang3, Yuanyuan Zhang4, Yuqian Sun, MD5, Xiao-Dong Mo, MD6, Yi-Fei Cheng, MD7, Lanping Xu, MD8, XiaoHui Zhang9, Xiaojun Huang, MD, PhD10
AFFILIATIONS
1 Peking University People's Hospital, Beijing, China
2 Peking University People's Hospital, Beijing, China
3 Peking University People's Hospital, Beijing, China
4 Peking University People's Hospital, Beijing, China
5 Peking University People's Hospital, Beijing, China
6 Peking University People's Hospital, Beijing, China
7 Peking University People's Hospital, Beijing, China
8 Peking University People's Hospital, Beijing, China
9 Peking University People's Hospital, Beijing, China
10 Peking University People's Hospital, Beijing, China
ABSTRACT
PURPOSE Outcomes are poor in TP53-mutant (mTP53) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), even after allogeneic hematopoietic stem-cell transplant (HCT). Interferonα (IFN-α) therapy, which can strengthen the GVL effect, has been reported as an efficient therapy in patients with AML or MDS..
PATIENTS AND METHODS We conducted a phase II, open-label trial to assess efficacy and safety of IFN-αas maintenance therapy after HCT (ClinicalTrials.gov identi?er: NCT06130579). IFN-α3 million units twice per week was scheduled subcutaneously on days 75 post HCT. Maintenance treatment was continued for a maximum of 12 months. The primary outcomes were relapse incidence and safety.
RESULTS Of the 95 patients screened for eligibility before HCT, 66 received a transplant. Forty-one patients ultimately received maintenance treatment (16 AML and 25 MDS); the median age was 52 (range, 17-66) years. The median duration of IFN-αadministration was 203 days (range, 13-650), and 16 patients (39%) completed 12 planned months of therapy. With a median follow-up of 18.9 months, The 1-year CIR rate was 18.2% (95% CI, 6.4 to 30.0); the median RFS was not reached; the 1-year RFS and 2-year probability was 77.9% (95% CI, 64.9 to 90.9) and 72.3% (95% CI, 56.1 to 88.5), respectively. The median overall survival (OS) was not reached; the 1-year and 2-year OS probability was 82.6% (95% CI, 70.6 to 94.6) and 79.6% (95% CI, 66.6 to 92.6), respectively. Thirty-day and 60- day mortality from the first dose were 0% . Acute and chronic (moderate to severe) graft- versus-host disease adverse events were reported in 2.4% (n = 1) and 24% (n = 10) of patients, respectively.
CONCLUSION In patients with mTP53 AML and MDS, post-HCT maintenance therapy with Interferonαwas well tolerated. RFS and OS outcomes were encouraging in this high-risk population.
DISCLOSURES
Yu Wang: No relevant conflicts of interest to declare.